| Name | Title | Contact Details |
|---|
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.
Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.